175 related articles for article (PubMed ID: 31493748)
1. CD47 promotes cell growth and motility in epithelial ovarian cancer.
Wang CL; Lin MJ; Hsu CY; Lin HY; Tsai HP; Long CY; Tsai EM; Hsieh TH; Wu CH
Biomed Pharmacother; 2019 Nov; 119():109105. PubMed ID: 31493748
[TBL] [Abstract][Full Text] [Related]
2. CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis.
Liu R; Wei H; Gao P; Yu H; Wang K; Fu Z; Ju B; Zhao M; Dong S; Li Z; He Y; Huang Y; Yao Z
Oncotarget; 2017 Jun; 8(24):39021-39032. PubMed ID: 28380460
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-200a Promotes Phagocytosis of Macrophages and Suppresses Cell Proliferation, Migration, and Invasion in Nasopharyngeal Carcinoma by Targeting CD47.
Zhao Y; Yu X; Tang H; Han R; Wang X; Wang J; Wang K; Li G
Biomed Res Int; 2020; 2020():3723781. PubMed ID: 32149101
[TBL] [Abstract][Full Text] [Related]
4. Exosomal CD47 Plays an Essential Role in Immune Evasion in Ovarian Cancer.
Shimizu A; Sawada K; Kobayashi M; Yamamoto M; Yagi T; Kinose Y; Kodama M; Hashimoto K; Kimura T
Mol Cancer Res; 2021 Sep; 19(9):1583-1595. PubMed ID: 34016744
[TBL] [Abstract][Full Text] [Related]
5. Moesin affects the plasma membrane expression and the immune checkpoint function of CD47 in human ovarian clear cell carcinoma.
Ito Y; Kobori T; Urashima Y; Ito T; Hotta K; Obata T
J Reprod Immunol; 2024 Feb; 161():104185. PubMed ID: 38141516
[TBL] [Abstract][Full Text] [Related]
6. CD133, CD47, and PD-L1 Expression in Ovarian High-grade Serous Carcinoma and Its Association with Metastatic Disease: A Cross-sectional Study.
Masadah R; Ikram D; Riadi R; Tangdiung Y; Nelwan BJ; Ghaznawie M; Rauf S; Faruk M
Asian Pac J Cancer Prev; 2024 Jan; 25(1):249-255. PubMed ID: 38285791
[TBL] [Abstract][Full Text] [Related]
7. TM4SF1 is a potential target for anti-invasion and metastasis in ovarian cancer.
Gao C; Yao H; Liu H; Feng Y; Yang Z
BMC Cancer; 2019 Mar; 19(1):237. PubMed ID: 30876464
[TBL] [Abstract][Full Text] [Related]
8. Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines.
Karnezis AN; Chen SY; Chow C; Yang W; Hendricks WPD; Ramos P; Briones N; Mes-Masson AM; Bosse T; Gilks CB; Trent JM; Weissman B; Huntsman DG; Wang Y
Gynecol Oncol; 2021 Feb; 160(2):568-578. PubMed ID: 33328126
[TBL] [Abstract][Full Text] [Related]
9. High expression of CD47 predicts adverse prognosis in Chinese patients and suppresses immune response in melanoma.
Fu W; Li J; Zhang W; Li P
Biomed Pharmacother; 2017 Sep; 93():1190-1196. PubMed ID: 28738534
[TBL] [Abstract][Full Text] [Related]
10. CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer.
Zhao H; Wang J; Kong X; Li E; Liu Y; Du X; Kang Z; Tang Y; Kuang Y; Yang Z; Zhou Y; Wang Q
Sci Rep; 2016 Jul; 6():29719. PubMed ID: 27411490
[TBL] [Abstract][Full Text] [Related]
11. Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies.
Dheilly E; Moine V; Broyer L; Salgado-Pires S; Johnson Z; Papaioannou A; Cons L; Calloud S; Majocchi S; Nelson R; Rousseau F; Ferlin W; Kosco-Vilbois M; Fischer N; Masternak K
Mol Ther; 2017 Feb; 25(2):523-533. PubMed ID: 28153099
[TBL] [Abstract][Full Text] [Related]
12. KDM6B promotes ovarian cancer cell migration and invasion by induced transforming growth factor-β1 expression.
Liang S; Yao Q; Wei D; Liu M; Geng F; Wang Q; Wang YS
J Cell Biochem; 2019 Jan; 120(1):493-506. PubMed ID: 30277596
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma.
Chang B; Meng J; Zhu H; Du X; Sun L; Wang L; Li S; Yang G
Diagn Pathol; 2018 Nov; 13(1):87. PubMed ID: 30428884
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma.
Goto H; Kojima Y; Matsuda K; Kariya R; Taura M; Kuwahara K; Nagai H; Katano H; Okada S
Eur J Cancer; 2014 Jul; 50(10):1836-1846. PubMed ID: 24726056
[TBL] [Abstract][Full Text] [Related]
15. DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells.
Zhang L; Zhang S; Li A; Zhang A; Zhang S; Chen L
Int J Mol Med; 2018 Dec; 42(6):3065-3072. PubMed ID: 30221689
[TBL] [Abstract][Full Text] [Related]
16. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
[TBL] [Abstract][Full Text] [Related]
17. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
[TBL] [Abstract][Full Text] [Related]
18. Concurrent Expression of CD47 and CD44 in Colorectal Cancer Promotes Malignancy.
Fujiwara-Tani R; Sasaki T; Ohmori H; Luo Y; Goto K; Nishiguchi Y; Mori S; Nakashima C; Mori T; Miyagawa Y; Kawahara I; Fujii K; Kishi S; Tatsumoto N; Kuniyasu H
Pathobiology; 2019; 86(4):182-189. PubMed ID: 31132784
[TBL] [Abstract][Full Text] [Related]
19. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy targeting the CD47/SIRPα axis.
Weiskopf K
Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
